Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

Johnson & Johnson (NYSE: JNJ) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...

Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $166 from $162 and keeps a Neutral rating on the ...

Guggenheim analyst Vamil Divan maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target of ...

Johnson Controls International named Joakim Weidemanis as chief executive officer and lifted its 2025 profit forecast on ...

Key Takeaways Johnson Controls shares led the S&P 500's gainers Wednesday morning after the company's first-quarter results ...

The institutional investor owned 3,686 shares of the company’s stock after purchasing an additional 100 shares during the quarter. Strategic Investment Advisors MI’s holdings in Johnson ...

Johnson & Johnson stands alone as a leader across ... closer to 2% annually between 2025 and 2030. We already view the company as undervalued, and if J&J achieves its long-term guidance, there ...

Johnson & Johnson (NYSE: JNJ) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the vaunted, 30-company Dow Jones Industrial Average that year. Yet ...

Johnson & Johnson's financial results are generally steady and consistent. Check out the chart of revenue and net income below. The company's balance sheet is rock solid and has earned it an AAA ...